title: Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis.
abstract: Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34+ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34+ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34+ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.
authors.affiliation: University Children's Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075 Ulm, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Mohr
authors.forename: Ralf Michael
authors.initials: RM
authors.lastname: Zwacka
authors.forename: Gergely
authors.initials: G
authors.lastname: Jarmy
authors.forename: Chirlei
authors.initials: C
authors.lastname: Büneker
authors.forename: Hubert
authors.initials: H
authors.lastname: Schrezenmeier
authors.forename: Konstanze
authors.initials: K
authors.lastname: Döhner
authors.forename: Christian
authors.initials: C
authors.lastname: Beltinger
authors.forename: Markus
authors.initials: M
authors.lastname: Wiesneth
authors.forename: Klaus-Michael
authors.initials: KM
authors.lastname: Debatin
authors.forename: Karsten
authors.initials: K
authors.lastname: Stahnke
mesh_terms: D015703:Antigens, CD / Q000502:physiology*; D018952:Antigens, CD34 / Q000276:immunology*; D017209:Apoptosis / Q000502:physiology*; D053181:Caspase 8; D020169:Caspases / Q000378:metabolism*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000276:immunology; D006801:Humans; D037181:Lectins, C-Type / Q000502:physiology*; D007938:Leukemia / Q000473:pathology*; D051920:NK Cell Lectin-Like Receptor Subfamily D
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D037181:Lectins, C-Type; D051920:NK Cell Lectin-Like Receptor Subfamily D; C505530:CASP8 protein, human; D053181:Caspase 8; D020169:Caspases